Gilead Sciences
GILD
$77.65
Share price
1.37%
Change (1 day)
-12.78%
Change (1 year)
Categories
Revenue for Gilead Sciences (GILD)
Revenue in 2023 (TTM): $27.39 B
According to Gilead Sciences's latest financial reports the company's current revenue (TTM) is $27.39 B. In 2022 the company made a revenue of $27.28 B a decrease over the years 2021 revenue that were of $27.30 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gilead Sciences from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $27.39 B | 0.4% |
| 2022 | $27.28 B | -0.09% |
| 2021 | $27.30 B | 10.6% |
| 2020 | $24.68 B | 9.98% |
| 2019 | $22.44 B | 1.46% |
| 2018 | $22.12 B | -15.24% |
| 2017 | $26.10 B | -14.09% |
| 2016 | $30.39 B | -6.89% |
| 2015 | $32.63 B | 31.13% |
| 2014 | $24.88 B | 122.2% |
| 2013 | $11.20 B | 15.45% |
| 2012 | $9.70 B | 15.71% |
| 2011 | $8.38 B | 5.48% |
| 2010 | $7.94 B | 13.38% |
| 2009 | $7.01 B | 31.4% |
| 2008 | $5.33 B | 26.14% |
| 2007 | $4.23 B | 39.78% |
| 2006 | $3.02 B | 49.19% |
| 2005 | $2.02 B | 53.13% |
| 2004 | $1.32 B | 52.63% |
| 2003 | $0.86 B | 85.92% |
| 2002 | $0.46 B | 99.68% |
| 2001 | $0.23 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $91.32 B | 233.41% | 🇺🇸 USA |
 Pfizer PFE | $68.53 B | 150.23% | 🇺🇸 USA |
 AbbVie ABBV | $55.13 B | 101.31% | 🇺🇸 USA |
 Eli Lilly LLY | $32.07 B | 17.10% | 🇺🇸 USA |
 Amgen AMGN | $26.83 B | -2.03% | 🇺🇸 USA |
 Biogen BIIB | $9.99 B | -63.51% | 🇺🇸 USA |
 Illumina ILMN | $4.46 B | -83.70% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | $9.65 B | -64.75% | 🇺🇸 USA |
 Merck MRK | $59.31 B | 116.55% | 🇺🇸 USA |